MediWound (NASDAQ: MDWD) Q1 2026 revenue drops as 2026 guidance held
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
MediWound Ltd. reported first quarter 2026 revenue of $1.5 million, down from $4.0 million in the first quarter of 2025, as it increased investment in its pipeline. The company reaffirmed full‑year 2026 revenue guidance of $24–26 million.
For the quarter ended March 31, 2026, MediWound recorded an operating loss of $8.0 million and a net loss of $3.0 million, compared with a net loss of $0.7 million a year earlier, driven mainly by higher research and development spending.
The global Phase III VALUE trial of EscharEx in venous leg ulcers is ongoing, with enrollment progressing more gradually than anticipated; an interim assessment and enrollment completion are expected by the end of the first quarter of 2027. For NexoBrid, a BARDA contract awarded to Vericel and other government and military initiatives are expected to support revenue growth in the second half of 2026.
As of March 31, 2026, MediWound held $44.6 million in cash, cash equivalents and short‑term bank deposits and reported Adjusted EBITDA of -$7.0 million for the quarter, reflecting continued operating losses as it advances late‑stage programs.
Positive
- None.
Negative
- None.
Insights
Q1 revenue declined sharply as R&D spending rose, but guidance and cash resources support ongoing development.
MediWound generated Q1 2026 revenue of $1.475M, down from $3.955M in Q1 2025, as it prioritizes pipeline investment. Research and development expenses increased to $5.185M, contributing to an operating loss of $7.98M and Adjusted EBITDA of -$6.958M.
Net loss was limited to $2.952M thanks to financial income of $5.011M, largely from warrant and grant revaluations. Cash, cash equivalents and short‑term deposits of $44.646M as of March 31, 2026 provide support for clinical and commercial plans.
The Phase III VALUE trial of EscharEx is enrolling more slowly than anticipated, with interim assessment and enrollment completion targeted by the end of Q1 2027. For NexoBrid, a BARDA contract awarded to Vericel and other government and military initiatives are expected to contribute to revenue growth in the second half of 2026, aligning with reaffirmed full‑year revenue guidance of $24–26M.
Key Figures
Q1 2026 revenue: $1.475M
Q1 2025 revenue: $3.955M
Full-year 2026 revenue guidance: $24–26M
+5 more
8 metrics
Q1 2026 revenue
$1.475M
Total revenues for the three months ended March 31, 2026
Q1 2025 revenue
$3.955M
Total revenues for the three months ended March 31, 2025
Full-year 2026 revenue guidance
$24–26M
Reaffirmed company revenue outlook for 2026
Q1 2026 net loss
$2.952M
Net loss for the three months ended March 31, 2026
Q1 2026 Adjusted EBITDA
-$6.958M
Adjusted EBITDA for the three months ended March 31, 2026
Cash and deposits
$44.646M
Cash, cash equivalents and short-term bank deposits as of March 31, 2026
Q1 2026 operating loss
$7.980M
Operating loss for the three months ended March 31, 2026
Basic and diluted EPS
-$0.23
Basic and diluted net loss per share for Q1 2026
Key Terms
Adjusted EBITDA, Phase III VALUE study, BARDA contract, non-IFRS financial measures, +1 more
5 terms
Adjusted EBITDA financial
"Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization..."
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Phase III VALUE study medical
"Enrollment continues in the EscharEx’s global Phase III VALUE study in venous leg ulcers..."
BARDA contract regulatory
"For NexoBrid, the BARDA contract awarded to Vericel, together with other government and military initiatives..."
A BARDA contract is an award from the U.S. government agency that pays to develop, test or buy vaccines, diagnostics, treatments, or other public-health countermeasures. For investors it acts like a combination of grant and pre-order: it provides non-dilutive funding (no new shares required), milestone payments and possible future purchase commitments, which lower technical and market risk and can speed revenue and valuation growth.
non-IFRS financial measures financial
"To supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure..."
Non-IFRS financial measures are company-reported numbers that modify or exclude items from standard accounting results so management can highlight what it sees as underlying business performance—common examples are adjusted EBITDA or adjusted earnings per share. They matter to investors because they can make trends clearer by removing unusual or noncash items, like cleaning lens smudges off a camera, but they require scrutiny since companies decide what to exclude and comparisons across firms may not be uniform.
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16..."
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
For the month of May 2026
Commission File Number: 001-36349
MediWound Ltd.
(Translation of registrant’s name into English)
(Translation of registrant’s name into English)
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On May 27, 2026, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update”. A copy of
this press release is attached to this Form 6-K as Exhibit 99.1.
The contents of this Report of Foreign Private Issuer on Form 6-K (including the information contained in Exhibit
99.1, but excluding quotes of senior management of the Company) are hereby incorporated by reference into the Company’s Registration Statements on (i) Form S-8, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2014, March
24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 5, 2021, August 9, 2022, August 15, 2023, March 19, 2025 and March 5, 2026 (Registration Nos. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697,
333-273997, 333-285897, and 333-294055, respectively), and (ii) Form F-3, filed with the SEC on March 31, 2023, August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Date: May 27, 2026
|
MEDIWOUND LTD.
By: /s/ Hani Luxenburg
Name: Hani Luxenburg
Title: Chief Financial Officer
|
EXHIBIT INDEX
The following exhibit is filed as part of this Form 6-K:
|
Exhibit
99.1
|
Description
Press release dated May 27, 2026 titled “MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update”.
|
Exhibit 99.1
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
EscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected
by the end of the first quarter of 2027
by the end of the first quarter of 2027
First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million
Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time
YAVNE, Israel, May 27, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced
financial results for the first quarter ended March 31, 2026, and provided a corporate update.
“During the first quarter, we continued to advance both our strategic and operational priorities,” said Ofer Gonen, Chief Executive
Officer of MediWound. “Enrollment continues in the EscharEx’s global Phase III VALUE study in venous leg ulcers, with more than 30 sites active across the U.S., Europe, and Israel. Enrollment has progressed more gradually than originally
anticipated, and we have implemented targeted actions to support recruitment momentum. We continue to see strong engagement from investigators and strategic collaborators and remain encouraged by the growing medical and commercial interest in
EscharEx.”
“For NexoBrid, the BARDA contract awarded to Vericel, together with other government and military initiatives, further underscores the importance of NexoBrid for national preparedness efforts and is
expected to contribute to revenue growth in the second half of 2026. We also remain focused on completing the regulatory and operational steps necessary to bring our expanded manufacturing capacity online.”
First Quarter 2026 Highlights, Recent Developments, and Upcoming Milestones
EscharEx®
| ● |
Enrollment continues in the global Phase III VALUE study in venous leg ulcers (VLUs), targeting 216 patients across approximately 40 sites in the U.S., Europe, and Israel. The pre-specified interim sample size
reassessment and enrollment completion are expected by the end of the first quarter of 2027.
|
| ● |
Medline (Nasdaq: MDLN) joined the EscharEx clinical development program through a research collaboration agreement, alongside existing collaborators Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun and MIMEDX. Together,
these collaborations include all major advanced wound care companies relevant to the program.
|
| ● |
A peer-reviewed U.S. expert consensus document was published in WOUNDS, underscoring the market need for effective, easy-to-use, and less invasive debridement modalities in chronic wound
care, reinforcing the clinical and commercial case for EscharEx.
|
| ● |
New clinical and preclinical data presented at the 2026 WHS, SAWC Spring, and EWMA conferences highlighted EscharEx’s clinical benefits, its distinct mechanism of action, and its broad potential across various chronic wound types,
including VLUs, DFUs, and pressure ulcers. The data also demonstrated the advantages of EscharEx over SANTYL, the leading biologic enzymatic debridement therapy with annual sales exceeding $400 million.
|
NexoBrid®
| ● |
U.S. adoption of NexoBrid continues to expand, with Vericel reporting growth in both the number of ordering centers and total orders across the U.S. burn care market.
|
| ● |
Vericel was awarded a ten-year BARDA contract valued at up to $197 million to support NexoBrid procurement, vendor-managed inventory services, potential blast-trauma indication development, and next-generation manufacturing and formulation
capabilities. Initial procurement activity is expected to begin in the second half of 2026.
|
| ● |
Commercial supply from the expanded NexoBrid manufacturing facility remains subject to regulatory approval. A recent on-site pre-audit by the European Medicines Agency (EMA) identified several recommended modifications, which the Company
expects to implement during the second half of 2026.
|
| ● |
New national consensus guidelines from Japan and the UK, published in the peer-reviewed European Burn Journal, add to existing European, WHO, and country-specific recommendations
from Italy, Spain, Romania, and Poland, further reinforce the growing role of NexoBrid in burn care worldwide.
|
| ● |
The peer-reviewed NEXT Expanded Access Program, published in the Journal of Burn Care & Research, presented real-world U.S. data from 239 adult and pediatric burn patients treated with
NexoBrid, showing rapid eschar removal, low rates of surgical excision, and a safety profile consistent with prior Phase III trials.
|
First Quarter 2026 Financial Highlights
| ● |
Revenue for the first quarter was $1.5 million, compared to $4.0 million in the first quarter of 2025. The decrease was primarily attributable to the timing of BARDA-related revenues, as well as postponed shipments related to regional
conflict.
|
| ● |
Gross profit was $0.3 million, representing a gross margin of 21.9%, compared to gross profit of $0.7 million, or a gross margin of 18.7%, in the first quarter of 2025.
|
| ● |
Research and development expenses were $5.2 million, compared to $2.9 million in the first quarter of 2025, primarily due to costs associated with the EscharEx VALUE Phase III trial.
|
| ● |
Selling, general and administrative expenses totaled $3.6 million, compared to $3.1 million in the prior-year quarter.
|
| ● |
Operating loss was $8.0 million, compared to $5.2 million in the first quarter of 2025.
|
| ● |
Net loss was $3.0 million, or $0.23 per share, compared to a net loss of $0.7 million, or $0.07 per share, in the first quarter of 2025.
|
| ● |
Non-GAAP Adjusted EBITDA loss was $7.0 million, compared to a loss of $4.0 million in the same period last year.
|
Balance Sheet and Other Highlights
| ● |
As of March 31, 2026, cash, cash equivalents, and deposits totaled $45 million, compared to $54 million as of December 31, 2025. The balance includes $1.2 million received under the European Innovation Council (EIC) Accelerator grant
program.
|
| ● |
Net cash used in operating activities during the first quarter of 2026 was $9.6 million.
|
| ● |
MediWound received $0.7 million from the exercise of Series A warrants after quarter-end.
|
| ● |
The Company reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, supported primarily by expected revenue from government-related development services during the second half of 2026.
|
Conference Call and Webcast
MediWound management will host a conference call for investors on Wednesday, May 27, 2026, beginning at 8:30 a.m., Eastern Time to
discuss these results and answer questions. Shareholders and other interested parties may join the conference call by dialing 1-844-676-8833 (in the U.S.), 1-809-212373 (Israel), or 1-412-634-6869 (outside the U.S. & Israel). The call will be
available via webcast by clicking HERE or on the Events & Presentations page of the Company’s website.
A replay of the call will be available on the Company’s website at www.mediwound.com.
Non-IFRS Financial Measures
To supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure to consider in evaluating the Company’s
performance. Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization, impairment, certain non-recurring expenses, restructuring and share-based compensation expenses.
Although Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with IFRS, we believe the non-IFRS financial measures we present provide meaningful supplemental
information regarding our operating results primarily because they exclude certain non-cash charges or items that we do not believe are reflective of our ongoing operating results when budgeting, planning and forecasting and determining compensation,
and when assessing the performance of our business with our senior management. However, investors should not consider these measures in isolation or as substitutes for operating income, cash flows from operating activities or any other measure for
determining the Company’s operating performance or liquidity that is calculated in accordance with IFRS. In addition, because Adjusted EBITDA is not calculated in accordance with IFRS, it may not necessarily be comparable to similarly titled measures
employed by other companies. The non-IFRS measures included in this press release have been reconciled to the IFRS results in the tables below.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated
for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for
the debridement of chronic wounds, with the potential to become, if approved, a new standard of care in wound management.
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).
Cautionary Note Regarding Forward-Looking Statements
MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect,
believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events
affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the
forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,”
“outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated
timelines, expectations and commercial potential of our products and product candidates, including EscharEx® and NexoBrid®. Among the factors that may cause results to be materially different from those stated herein are the
inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current
and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and
product candidates in the U.S. or other markets; our contracts with governmental agencies; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products candidates; our
expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; geopolitical
risks, including armed conflict, the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or
capacity to manufacture, sell and support the use of our products and product candidates in the future.
These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2025, filed with the Securities and
Exchange Commission (“SEC”) on March 5, 2026 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound undertakes, and
specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.
|
MediWound Contacts:
|
|
|
Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
|
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
|
MediWound Ltd.
Unaudited Condensed Consolidated Statements of Financial Position
U.S. dollars in thousands
|
March 31,
|
December 31,
|
|||||||||||
|
2026
|
2025
|
2025
|
||||||||||
|
CURRENT ASSETS:
|
||||||||||||
|
Cash and cash equivalents and short-term bank deposits
|
44,646
|
38,266
|
53,140
|
|||||||||
|
Trade and other receivable, net
|
2,748
|
5,176
|
2,731
|
|||||||||
|
Inventories
|
4,772
|
3,580
|
4,093
|
|||||||||
|
Total current assets
|
52,166
|
47,022
|
59,964
|
|||||||||
|
NON-CURRENT ASSETS:
|
||||||||||||
|
Other receivables and long-term restricted bank deposit
|
467
|
485
|
467
|
|||||||||
|
Property, plant and equipment
|
20,272
|
14,743
|
18,640
|
|||||||||
|
Right of use assets
|
7,060
|
6,683
|
7,151
|
|||||||||
|
Intangible assets
|
17
|
83
|
33
|
|||||||||
|
Total non-current assets
|
27,816
|
21,994
|
26,291
|
|||||||||
|
Total assets
|
79,982
|
69,016
|
86,255
|
|||||||||
|
CURRENT LIABILITIES:
|
||||||||||||
|
Current maturities of long-term liabilities
|
929
|
688
|
870
|
|||||||||
|
Warrants
|
7,723
|
12,822
|
12,659
|
|||||||||
|
Trade payables and accrued expenses
|
7,408
|
4,992
|
7,648
|
|||||||||
|
Other payables
|
5,586
|
3,341
|
4,531
|
|||||||||
|
Total current liabilities
|
21,646
|
21,843
|
25,708
|
|||||||||
|
NON-CURRENT LIABILITIES:
|
||||||||||||
|
Grants received in advance
|
-
|
736
|
-
|
|||||||||
|
Liabilities in respect of IIA grants
|
8,492
|
8,310
|
8,291
|
|||||||||
|
Lease liabilities
|
8,126
|
6,424
|
8,152
|
|||||||||
|
Severance pay liability, net
|
295
|
431
|
472
|
|||||||||
|
Total non-current liabilities
|
16,913
|
15,901
|
16,915
|
|||||||||
|
Total liabilities
|
38,559
|
37,744
|
42,623
|
|||||||||
|
Shareholders' equity
|
41,423
|
31,272
|
43,632
|
|||||||||
|
Total liabilities & equity
|
79,982
|
69,016
|
86,255
|
|||||||||
MediWound Ltd.
Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss
U.S. dollars in thousands (except of share and per share data)
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
|
2026
|
2025
|
2025
|
||||||||||
|
Total Revenues
|
1,475
|
3,955
|
16,959
|
|||||||||
|
Cost of revenues
|
1,152
|
3,217
|
13,705
|
|||||||||
|
Gross profit
|
323
|
738
|
3,254
|
|||||||||
|
Research and development
|
5,185
|
2,886
|
14,320
|
|||||||||
|
Selling and marketing
|
1,257
|
1,287
|
5,765
|
|||||||||
|
General and administrative
|
2,300
|
1,786
|
8,448
|
|||||||||
|
Other (income) expenses, net
|
(439
|
)
|
4
|
(13
|
)
|
|||||||
|
Operating loss
|
(7,980
|
)
|
(5,225
|
)
|
(25,266
|
)
|
||||||
|
Financial income, net
|
5,011
|
4,504
|
1,556
|
|||||||||
|
Taxes on income
|
17
|
(5
|
)
|
(169
|
)
|
|||||||
|
Net loss
|
(2,952
|
)
|
(726
|
)
|
(23,879
|
)
|
||||||
|
Foreign currency translation adjustments
|
6
|
1
|
(21
|
)
|
||||||||
|
Total comprehensive loss
|
(2,946
|
)
|
(725
|
)
|
(23,900
|
)
|
||||||
|
Basic and diluted net loss per share
|
(0.23
|
)
|
(0.07
|
)
|
(2.10
|
)
|
||||||
|
Number of shares used in calculating basic and diluted loss per share
|
12,874,062
|
10,798,318
|
11,376,571
|
|||||||||
MediWound Ltd.
Unaudited Condensed Consolidated Statements of Cash Flows
U.S. dollars in thousands
|
Three months ended
|
Year Ended
|
|||||||||||
|
March 31,
|
December 31,
|
|||||||||||
|
2026
|
2025
|
2025
|
||||||||||
|
Cash Flows from Operating Activities:
|
||||||||||||
|
Net loss
|
(2,952
|
)
|
(726
|
)
|
(23,879
|
)
|
||||||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
|
Adjustments to profit and loss items:
|
||||||||||||
|
Depreciation and amortization
|
378
|
358
|
1,860
|
|||||||||
|
Share-based compensation
|
644
|
844
|
3,108
|
|||||||||
|
Revaluation of warrants accounted at fair value
|
(4,936
|
)
|
(4,270
|
)
|
(2,158
|
)
|
||||||
|
Revaluation of liabilities in respect of IIA grants
|
234
|
243
|
380
|
|||||||||
|
Financing income and exchange differences of lease liability
|
235
|
5
|
1,725
|
|||||||||
|
Increase (decrease) in severance liability, net
|
(156
|
)
|
27
|
31
|
||||||||
|
Other (income) expenses
|
(439
|
)
|
4
|
(13
|
)
|
|||||||
|
Financial income, net
|
(534
|
)
|
(518
|
)
|
(1,891
|
)
|
||||||
|
Unrealized foreign currency loss (gain)
|
16
|
(15
|
)
|
(51
|
)
|
|||||||
|
(4,558
|
)
|
(3,322
|
)
|
2,991
|
||||||||
|
Changes in asset and liability items:
|
||||||||||||
|
Decrease in trade receivables
|
395
|
1,454
|
3,211
|
|||||||||
|
Increase in inventories
|
(686
|
)
|
(888
|
)
|
(1,363
|
)
|
||||||
|
Decrease (increase) in other receivables
|
(733
|
)
|
(378
|
)
|
1,665
|
|||||||
|
Increase (decrease) in trade payables and accrued expenses
|
(188
|
)
|
(103
|
)
|
2,350
|
|||||||
|
Increase in grants received in advance
|
1,163
|
-
|
-
|
|||||||||
|
Increase (decrease) in other payables
|
805
|
(147
|
)
|
(1,096
|
)
|
|||||||
|
756
|
(62
|
)
|
4,767
|
|||||||||
|
Net cash used in operating activities
|
(6,754
|
)
|
(4,110
|
)
|
(16,121
|
)
|
||||||
MediWound Ltd.
Unaudited Condensed Consolidated Statements of Cash Flows
U.S. dollars in thousands
|
Three months ended
March 31,
|
Year Ended
December 31, |
|||||||||||
|
2026
|
2025
|
2025
|
||||||||||
|
Cash Flows from Investment Activities:
|
||||||||||||
|
Purchase of property and equipment
|
(1,820
|
)
|
(959
|
)
|
(5,505
|
)
|
||||||
|
Interest received
|
576
|
266
|
1,591
|
|||||||||
|
Proceeds from (investment in) short term bank deposits, net
|
19,000
|
(2,650
|
)
|
(14,036
|
)
|
|||||||
|
Net cash provided by (used in) investing activities
|
17,756
|
(3,343
|
)
|
(17,950
|
)
|
|||||||
|
Cash Flows from Financing Activities:
|
||||||||||||
|
Repayment of lease liabilities
|
(337
|
)
|
(248
|
)
|
(1,212
|
)
|
||||||
|
Proceeds from exercise of warrants and share options
|
-
|
-
|
3,630
|
|||||||||
|
Proceeds from issuance of shares
|
-
|
-
|
27,416
|
|||||||||
|
Repayments of IIA grants, net
|
(84
|
)
|
(114
|
)
|
(214
|
)
|
||||||
|
Net cash provided by (used in) financing activities
|
(421
|
)
|
(362
|
)
|
29,620
|
|||||||
|
Exchange rate differences on cash and cash equivalent balances
|
(29
|
)
|
19
|
95
|
||||||||
|
Increase (decrease) in cash and cash equivalents
|
10,552
|
(7,796
|
)
|
(4,356
|
)
|
|||||||
|
Balance of cash and cash equivalents at the beginning of the period
|
4,799
|
9,155
|
9,155
|
|||||||||
|
Balance of cash and cash equivalents at the end of the period
|
15,351
|
1,359
|
4,799
|
|||||||||
MediWound Ltd.
Adjusted EBITDA
U.S. dollars in thousands
|
Three months ended
|
Year ended
|
|||||||||||
|
March 31,
|
December 31,
|
|||||||||||
|
2026
|
2025
|
2025
|
||||||||||
|
Net loss
|
(2,952
|
)
|
(726
|
)
|
(23,879
|
)
|
||||||
|
Adjustments:
|
||||||||||||
|
Financial income, net
|
5,011
|
4,504
|
1,556
|
|||||||||
|
Other (income) expenses, net
|
-
|
(4
|
)
|
13
|
||||||||
|
Taxes on income
|
17
|
(5
|
)
|
(169
|
)
|
|||||||
|
Depreciation and amortization
|
(378
|
)
|
(358
|
)
|
(1,860
|
)
|
||||||
|
Share-based compensation expenses
|
(644
|
)
|
(844
|
)
|
(3,108
|
)
|
||||||
|
Total adjustments
|
4,006
|
3,293
|
(3,568
|
)
|
||||||||
|
Adjusted EBITDA
|
(6,958
|
)
|
(4,019
|
)
|
(20,311
|
)
|
||||||
FAQ
How did MediWound (MDWD) perform financially in Q1 2026?
MediWound reported Q1 2026 revenue of $1.475 million and a net loss of $2.952 million. Operating loss reached $7.980 million as research and development spending rose, while financial income of $5.011 million partially offset operating losses for the quarter ended March 31, 2026.
What revenue guidance did MediWound (MDWD) provide for full-year 2026?
MediWound reaffirmed its full-year 2026 revenue guidance of $24–26 million. This outlook reflects expectations for contributions from NexoBrid, including a BARDA-related contract and other government and military initiatives, particularly in the second half of 2026.
What is the status of MediWound’s EscharEx Phase III VALUE trial?
Enrollment in MediWound’s global Phase III VALUE study of EscharEx for venous leg ulcers is ongoing but slower than anticipated. More than 30 sites are active, and an interim assessment and enrollment completion are expected by the end of the first quarter of 2027.
How is NexoBrid expected to impact MediWound’s 2026 revenue?
For NexoBrid, a BARDA contract awarded to Vericel and additional government and military initiatives are expected to support revenue growth in the second half of 2026. These programs underscore NexoBrid’s role in national preparedness and potential future sales contributions.
What was MediWound’s cash position as of March 31, 2026?
As of March 31, 2026, MediWound held $44.646 million in cash, cash equivalents and short-term bank deposits. This balance, alongside total assets of $79.982 million, supports the company’s ongoing clinical development and commercial activities.
What was MediWound’s Adjusted EBITDA in Q1 2026?
MediWound reported Adjusted EBITDA of negative $6.958 million for Q1 2026. This non-IFRS metric excludes items such as financial income, taxes, depreciation, amortization and share-based compensation, highlighting underlying operating losses as the company invests in its portfolio.
How did MediWound’s R&D spending change in Q1 2026 versus Q1 2025?
Research and development expenses increased to $5.185 million in Q1 2026 from $2.886 million in Q1 2025. The higher spending reflects greater investment in late-stage programs such as the EscharEx Phase III VALUE trial and related development activities.